Atara Biotherapeutics Stock News

Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares, rose in value on Friday, 12/17/21, with the stock price down by -0.79% to the previous days close as strong demand from buyers drove the stock to $15.15. Actively observing the price movement in the last trading, the stock closed the session at $15.27, falling within a range of $14.77 Read This First Before You Buy Atara Biotherapeutics Inc. (NASDAQ: ATRA) Stock Read More »

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) gapped up prior to trading on Tuesday . The stock had previously closed at $15.66, but opened at $16.99. Atara Biotherapeutics shares last traded at $15.57, with a volume of 546 shares trading hands. A number of research firms have recently commented on ATRA. Mizuho began coverage on shares of Atara […]

NEW YORK , Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KPLT, ATRA, CLSK, LICY, and LCID. Full story available on Benzinga.com

Atara Biotherapeutics Inc (NASDAQ: ATRA ) posted efficacy and safety results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). EBV+ PTLD is a rare complication after a solid organ (SOT) or hematopoietic stem cell transplant (HSCT). The overall response rate was 50% in both the SOT and HCT groups. 26.3% of patients overall achieved a complete response, and just under 23.7% reached a partial response. Eleven of … Full story available on Benzinga.com

Atara has been stagnant because of more than a year's worth of delay caused by the CMC review division at the FDA. I see no immediate end to the process; however, this has nearly nothing to do with th

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given an average recommendation of Buy by the seven analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have []

Invesco Ltd. grew its holdings in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 32.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 47,917 shares of the biotechnology companys stock after purchasing an additional 11,758 shares during the quarter. Invesco Ltd. owned about 0.06% of Atara Biotherapeutics []

Wall Street analysts predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will announce $32.47 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Atara Biotherapeutics earnings. The highest sales estimate is $50.60 million and the lowest is $3.87 million. The firm is expected to announce its next earnings []

Equities research analysts expect that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will report sales of $32.47 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Atara Biotherapeutics earnings. The highest sales estimate is $50.60 million and the lowest is $3.87 million. The firm is expected to announce its next earnings report []

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Jakob Dupont sold 2,199 shares of the companys stock in a transaction on Tuesday, November 16th. The stock was sold at an average price of $17.12, for a total value of $37,646.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed []